DMG Mori (6141) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
9 Jun, 2025Executive summary
FY2024 sales revenue rose 0.3% year-over-year to JPY 540.9 bn, but operating profit fell 21% to JPY 43.7 bn and net profit dropped 77.3% to JPY 7.7 bn due to one-time losses from discontinued Russian operations.
Order intake declined 4.6% year-over-year to JPY 496.0 bn, with a lower machine order backlog at year-end; average machine order unit price increased 15% to JPY 71.0 mil, driven by higher MX solution adoption and automation.
Spare parts and services grew to 25% of order intake.
Regional order intake: Asia (ex-China) up 8%, Americas flat, Europe down 4%, Japan down 8%, China down 24%.
Major developments include near-complete acquisition of TAIYO KOKI, groundbreaking for European HQ in Munich, and Iga Campus winning the Deming Prize.
Financial highlights
Operating profit margin decreased to 8.1% from 10.3% in FY2023.
Dividend per share increased to JPY 100, with a plan to raise it to JPY 105 in FY2025.
Shareholders' equity ratio improved to 39.4% due to CB conversion; net D/E ratio at 0.20.
Cash flows from operating activities were JPY 44.6 bn; cash and equivalents at year-end were JPY 41.7 bn.
Free cash flow in 4Q was JPY 21.9 bn, with FY2025 free cash flow planned at JPY 20.0 bn or more.
Outlook and guidance
FY2025 forecast: sales revenue JPY 510.0 bn (-5.7% y-o-y), operating profit JPY 38.0 bn (-13.1% y-o-y), profit attributable to owners of the parent JPY 20.0 bn (up 159.7%), OP margin 7.5%, EPS 129.40 yen.
Lower revenue expected due to reduced order backlog and slow order recovery; insurance claim for Russian plant seizure not included in forecast.
Plan to convert order backlog of JPY 218.0 bn into sales and generate new orders.
FY2030 targets: sales revenue JPY 800 bn, OP margin 15%, net profit margin 10%, dividend per share JPY 200.
Latest events from DMG Mori
- FY2025 saw order and profit recovery, but FY2026 profit is set to drop sharply with stable dividends.6141
Q4 202510 Feb 2026 - Order intake steady, sales and EBIT down, net profit rebounded on insurance proceeds.6141
Q3 202530 Oct 2025 - Order intake and average order price rose, but sales and profits declined sharply year-over-year.6141
Q2 20251 Aug 2025 - Net profit collapsed on Russian exit, prompting lower full-year guidance despite stable sales.6141
Q3 202413 Jun 2025 - Upward order revision and margin gains signal strong growth despite one-time Russian loss.6141
Q2 202413 Jun 2025 - Profit and revenue declined, but order intake and sustainability efforts support recovery.6141
Q1 20259 Jun 2025